199 related articles for article (PubMed ID: 37980571)
1. Genome-wide profiling of transcription factor activity in primary liver cancer using single-cell ATAC sequencing.
Craig AJ; Silveira MAD; Ma L; Revsine M; Wang L; Heinrich S; Rae Z; Ruchinskas A; Dadkhah K; Do W; Behrens S; Mehrabadi FR; Dominguez DA; Forgues M; Budhu A; Chaisaingmongkol J; Hernandez JM; Davis JL; Tran B; Marquardt JU; Ruchirawat M; Kelly M; Greten TF; Wang XW
Cell Rep; 2023 Nov; 42(11):113446. PubMed ID: 37980571
[TBL] [Abstract][Full Text] [Related]
2. MYC determines lineage commitment in KRAS-driven primary liver cancer development.
D'Artista L; Moschopoulou AA; Barozzi I; Craig AJ; Seehawer M; Herrmann L; Minnich M; Kang TW; Rist E; Henning M; Klotz S; Heinzmann F; Harbig J; Sipos B; Longerich T; Eilers M; Dauch D; Zuber J; Wang XW; Zender L
J Hepatol; 2023 Jul; 79(1):141-149. PubMed ID: 36906109
[TBL] [Abstract][Full Text] [Related]
3. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
4. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
Lee YT; Wang JJ; Luu M; Noureddin M; Nissen NN; Patel TC; Roberts LR; Singal AG; Gores GJ; Yang JD
Hepatology; 2021 Nov; 74(5):2622-2632. PubMed ID: 34114675
[TBL] [Abstract][Full Text] [Related]
6. Gut dysbiosis in Thai intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
Pomyen Y; Chaisaingmongkol J; Rabibhadana S; Pupacdi B; Sripan D; Chornkrathok C; Budhu A; Budhisawasdi V; Lertprasertsuke N; Chotirosniramit A; Pairojkul C; Auewarakul CU; Ungtrakul T; Sricharunrat T; Phornphutkul K; Sangrajang S; Loffredo CA; Harris CC; Mahidol C; Wang XW; Ruchirawat M;
Sci Rep; 2023 Jul; 13(1):11406. PubMed ID: 37452065
[TBL] [Abstract][Full Text] [Related]
7. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the distinct immune microenvironments between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Jiang S; Lu H; Pan Y; Yang A; Aikemu A; Li H; Hao R; Huang Q; Qi X; Tao Z; Wu Y; Quan C; Zhou G; Lu Y
Cancer Lett; 2024 Apr; 588():216799. PubMed ID: 38479553
[TBL] [Abstract][Full Text] [Related]
9. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
Sia D; Villanueva A; Friedman SL; Llovet JM
Gastroenterology; 2017 Mar; 152(4):745-761. PubMed ID: 28043904
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of Acylphosphatase 1 Expression in Combined HCC-iCCA, HCC, and iCCA.
Sakano Y; Noda T; Kobayashi S; Kitagawa A; Iwagami Y; Yamada D; Tomimaru Y; Akita H; Gotoh K; Asaoka T; Tanemura M; Umeshita K; Mimori K; Doki Y; Eguchi H
Dig Dis Sci; 2022 Aug; 67(8):3817-3830. PubMed ID: 34626299
[TBL] [Abstract][Full Text] [Related]
11. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
[TBL] [Abstract][Full Text] [Related]
12. Tumor Microenvironment: Necroptosis Switches the Subtype of Liver Cancer While Necrosis Promotes Tumor Recurrence and Progression.
Özdemir BH
Exp Clin Transplant; 2023 Apr; 21(4):291-298. PubMed ID: 35297332
[TBL] [Abstract][Full Text] [Related]
13. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
An J; Kim D; Oh B; Oh YJ; Song J; Park N; Kim HI; Kang HJ; Oh JH; Kim W; Lee E; Sung CO; Song GW; Kim DG; Yu E; Letouzé E; Zucman-Rossi J; Lee HC; Shim JH
Hepatology; 2022 Apr; 75(4):997-1011. PubMed ID: 34478159
[TBL] [Abstract][Full Text] [Related]
15. Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma.
Calderaro J; Ghaffari Laleh N; Zeng Q; Maille P; Favre L; Pujals A; Klein C; Bazille C; Heij LR; Uguen A; Luedde T; Di Tommaso L; Beaufrère A; Chatain A; Gastineau D; Nguyen CT; Nguyen-Canh H; Thi KN; Gnemmi V; Graham RP; Charlotte F; Wendum D; Vij M; Allende DS; Aucejo F; Diaz A; Rivière B; Herrero A; Evert K; Calvisi DF; Augustin J; Leow WQ; Leung HHW; Boleslawski E; Rela M; François A; Cha AW; Forner A; Reig M; Allaire M; Scatton O; Chatelain D; Boulagnon-Rombi C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Pawlotsky JM; Zhang X; Luciani A; Mulé S; Laurent A; Amaddeo G; Regnault H; De Martin E; Sempoux C; Navale P; Westerhoff M; Lo RC; Bednarsch J; Gouw A; Guettier C; Lequoy M; Harada K; Sripongpun P; Wetwittayaklang P; Loménie N; Tantipisit J; Kaewdech A; Shen J; Paradis V; Caruso S; Kather JN
Nat Commun; 2023 Dec; 14(1):8290. PubMed ID: 38092727
[TBL] [Abstract][Full Text] [Related]
16. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
Alvisi G; Termanini A; Soldani C; Portale F; Carriero R; Pilipow K; Costa G; Polidoro M; Franceschini B; Malenica I; Puccio S; Lise V; Galletti G; Zanon V; Colombo FS; De Simone G; Tufano M; Aghemo A; Di Tommaso L; Peano C; Cibella J; Iannacone M; Roychoudhuri R; Manzo T; Donadon M; Torzilli G; Kunderfranco P; Di Mitri D; Lugli E; Lleo A
J Hepatol; 2022 Nov; 77(5):1359-1372. PubMed ID: 35738508
[TBL] [Abstract][Full Text] [Related]
17. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
Komuta M
Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
[TBL] [Abstract][Full Text] [Related]
18. Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features.
Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
Histopathology; 2019 Sep; 75(3):385-393. PubMed ID: 31017316
[TBL] [Abstract][Full Text] [Related]
19. Tumor ratio of unsaturated to saturated sulfatide species is associated with disease-free survival in intrahepatic cholangiocarcinoma.
Huizing L; Chen L; Roeth AA; Heij LR; Flinders B; Bouwense SAW; Balluff B; Neumann UP; Heeren RMA; Olde Damink SWM; Vreeken RJ; Schaap FG
Cell Oncol (Dordr); 2023 Jun; 46(3):629-642. PubMed ID: 36630049
[TBL] [Abstract][Full Text] [Related]
20. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
